Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120,138,422
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
33,776,828
-
Shares change
-
+1,093,678
-
Total reported value, excl. options
-
$1,021,408,758
-
Value change
-
+$33,104,690
-
Number of buys
-
32
-
Number of sells
-
-14
-
Price
-
$30.24
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q2 2020
59 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q2 2020.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33,776,828 shares
of 120,138,422 outstanding shares and own 28% of the company stock.
Largest 10 shareholders include FRAZIER MANAGEMENT LLC (10,542,790 shares), FMR LLC (5,723,182 shares), ORBIMED ADVISORS LLC (4,673,850 shares), Bain Capital Life Sciences Investors, LLC (3,979,292 shares), BlackRock Inc. (1,566,574 shares), Vivo Capital, LLC (1,289,360 shares), RA CAPITAL MANAGEMENT, L.P. (1,165,184 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,066,540 shares), Omega Fund Management, LLC (844,680 shares), and WELLS FARGO & COMPANY/MN (527,127 shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.